Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 100

Results For "TD"

1473 News Found

Glenmark launches AKYNZEO I.V. in India
News | January 24, 2023

Glenmark launches AKYNZEO I.V. in India

It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV


Moderna announces an investigational respiratory syncytial vaccine mRNA-1345
News | January 23, 2023

Moderna announces an investigational respiratory syncytial vaccine mRNA-1345

mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults


Marksans Pharma raises Rs. 372.40 crores
News | January 21, 2023

Marksans Pharma raises Rs. 372.40 crores

OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.


Briefs: Bafna Pharmaceuticals, Strides Pharma, IOL Chemicals and Pharmaceuticals and Krsnaa Diagnostics
News | January 21, 2023

Briefs: Bafna Pharmaceuticals, Strides Pharma, IOL Chemicals and Pharmaceuticals and Krsnaa Diagnostics

The National Institute of Pharmacy and Nutrition, Hungary has issued 'Certificate of GMP Compliance of Manufacturer' for IOL Chemicals and Pharmaceuticals Limited's products.


Mandaviya urges stakeholders to partner with India to leverage opportunities at WEF Davos
News | January 19, 2023

Mandaviya urges stakeholders to partner with India to leverage opportunities at WEF Davos

India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery


Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets
News | January 18, 2023

Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets

Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)


Glenmark to divest select dermatology brands for Rs. 340.48 Cr
News | January 18, 2023

Glenmark to divest select dermatology brands for Rs. 340.48 Cr

The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands


USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions
Drug Approval | January 17, 2023

USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions

The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22


Dr. Reddy’s acquires trademark rights of breast cancer drug PRIMCYV from Pfizer
News | January 14, 2023

Dr. Reddy’s acquires trademark rights of breast cancer drug PRIMCYV from Pfizer

Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA


Genome sequencing solutions will help to bring precision in lung cancer therapy, says GlobalData
News | January 12, 2023

Genome sequencing solutions will help to bring precision in lung cancer therapy, says GlobalData

APAC region contributed around 50% of the in-vitro diagnostics market in 2022